Polypeptide-Based Molecular Platform and Its Docetaxel/Sulfo-Cy5-Containing Conjugate for Targeted Delivery to Prostate Specific Membrane Antigen
Autor: | Nikolay V. Zyk, Anastasia S. Garanina, Anastasia A. Uspenskaya, Yuri K. Grishin, Aleksei E. Machulkin, Vladimir I. Polshakov, Ekaterina A. Nimenko, Rostislav A Petrov, Nikolay Y. Zyk, Vitaly A. Roznyatovsky, Stanislav A. Petrov, Elena K. Beloglazkina, Alexander G. Majouga |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Glutamate Carboxypeptidase II
Pharmaceutical Science Chemistry Techniques Synthetic Tripeptide PSMA conjugate 01 natural sciences Article Analytical Chemistry lcsh:QD241-441 03 medical and health sciences chemistry.chemical_compound Drug Delivery Systems 0302 clinical medicine lcsh:Organic chemistry Amide Drug Discovery peptide synthesis Glutamate carboxypeptidase II Peptide synthesis Moiety docetaxel Amino Acid Sequence Physical and Theoretical Chemistry Drug Carriers Molecular Structure 010405 organic chemistry Organic Chemistry Carbocyanines prostate cancer Combinatorial chemistry 0104 chemical sciences Sulfo-Cy5 theranostic agent anticancer drugs chemistry Chemistry (miscellaneous) 030220 oncology & carcinogenesis Antigens Surface Molecular Medicine Azide Peptides Linker Conjugate |
Zdroj: | Molecules, Vol 25, Iss 5784, p 5784 (2020) Molecules Volume 25 Issue 24 |
ISSN: | 1420-3049 |
Popis: | A strategy for stereoselective synthesis of molecular platform for targeted delivery of bimodal therapeutic or theranostic agents to the prostate-specific membrane antigen (PSMA) receptor was developed. The proposed platform contains a urea-based, PSMA-targeting Glu-Urea-Lys (EuK) fragment as a vector moiety and tripeptide linker with terminal amide and azide groups for subsequent addition of two different therapeutic and diagnostic agents. The optimal method for this molecular platform synthesis includes (a) solid-phase assembly of the polypeptide linker, (b) coupling of this linker with the vector fragment, (c) attachment of 3-aminopropylazide, and (d) amide and carboxylic groups deprotection. A bimodal theranostic conjugate of the proposed platform with a cytostatic drug (docetaxel) and a fluorescent label (Sulfo-Cy5) was synthesized to demonstrate its possible sequential conjugation with different functional molecules. |
Databáze: | OpenAIRE |
Externí odkaz: |